Robust differentiation of human pluripotent stem cells into Schwann cells.

Autor: Tooi N; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan., Okama R; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan., Sato H; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan., Inose H; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan., Ogasawara H; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan., Senda H; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan., Nakatsuji N; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan; Kyoto University, Kyoto, Japan., Kato K; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan., Kiboku T; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan. Electronic address: takayuki.kiboku@scad-kyoto.com., Igura K; Stem Cell & Device Laboratory, Inc, OFFICE-ONE Shijo Karasuma 11F, 480, Niwatoriboko-cho, Shimogyo-ku, Kyoto, 600-8491, Japan. Electronic address: koichi.igura@scad-kyoto.com.
Jazyk: angličtina
Zdroj: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Oct 15; Vol. 729, pp. 150353. Date of Electronic Publication: 2024 Jul 04.
DOI: 10.1016/j.bbrc.2024.150353
Abstrakt: Research into Schwann cell (SC)-related diseases has been hampered by the difficulty of obtaining human-derived SCs, which have limited proliferative capacity. This has resulted in a delay in progress in drug discovery and cell therapy targeting SCs. To overcome these limitations, we developed a robust method for inducing the differentiation of human induced pluripotent stem cells (hiPSCs) into SCs. We established hiPSC lines and successfully generated high-purity Schwann cell precursors (SCPs) from size-controlled hiPSC aggregates by precisely timed treatment with our proprietary enzyme solution. Such SCPs were successfully expanded and further differentiated into myelin basic protein (MBP) expressing SC populations when treated with an appropriate medium containing dibutyryl-cAMP (db-cAMP). These differentiated cells secreted factors that induced neurite outgrowth in vitro. Our method allows for the efficient and stable production of SCPs and SCs from hiPSCs. This robust induction and maturation method has the potential to be a valuable tool in drug discovery and cell therapy targeting SC-related diseases.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: